TREATMENT OF HUMAN CUTANEOUS SPOROTRICHOSIS WITH ITRACONAZOLE
TREATMENT OF HUMAN CUTANEOUS SPOROTRICHOSIS WITH ITRACONAZOLE
复制标题
DOI：
10.1111/j.1439-0507.1992.tb00836.x
复制
发表时间：
1992-05-01
期刊：
影响因子：
4.9
通讯作者：
ALZUETA, G
中科院分区：
文献类型：
--
作者：
DIAZ, IAC;CIVILA, E;ALZUETA, G
十八名患有皮肤孢子丝菌病的成年白人男性患者按照不同的每日剂量方案接受伊曲康唑治疗。总剂量在 3.1 至 14.8 克（中位 8.4 克）之间，15-75 天（中位 44 天）后，所有病例均获得治愈。在 1 至 26 个月的随访期间（中位数 14.7），没有观察到严重的副作用，也没有发生复发。这些结果表明伊曲康唑是治疗孢子丝菌病的安全有效的药物。与其他研究的比较使我们认为每日 200 毫克的剂量是最合适的。应建议同时对受影响的肢体进行保暖。
Eighteen adult white male patients with cutaneous sporotrichosis were treated with itraconazole following different daily dose schemes. Cure was obtained in all cases after periods of 15-75 days (median 44 days) with total doses between 3.1 and 14.8 g (median 8.4 g). No serious side effects were observed and no relapses occurred in the follow-up period of between 1 and 26 months (median 14.7). These results show that itraconazole represents a safe and effective drug for the treatment of sporotrichosis. Comparison with other studies leads us to consider a daily dose of 200 mg as the most appropriate. A concomitant warming of the affected limbs should be recommended.